| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.024 | 0.4 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.4 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |